83-200, г. Starogard Gdanski, Koteze, ул. Sokola 1, Польша
Tел./факс: (+48) 58 531 02 59
Tел: (+48) 606 93 82 51

Brexit and EU rules in the field of clinical trials (CTs)

  • 5 марта 2019
  • Brexit, clinical trials, CT, database, EC, EudraCT, IMP, import, investigational medicinal product, legal consequences, notice, sponsor, UK's withdrawal,

ASE Pharma Solutions

In view of the considerable uncertainties, in particular concerning the content of a possible withdrawal agreement, sponsors (both academic researchers and pharmaceutical companies) conducting or planning to conduct clinical trials, as well as investigators and other persons involved in the preparation and conduct of clinical trials in the EU are reminded of legal repercussions, which need to be considered when the United Kingdom becomes a third country.

Subject to any transitional arrangement that may be contained in a possible withdrawal agreement, as of the withdrawal date, the EU rules on clinical trials, and in particular Directive 2001/20/EC no longer apply to the United Kingdom. This has, in particular, the consequences in the following areas:

woman in hospital

 

SUPPLY OF INVESTIGATIONAL MEDICINAL PRODUCTS



union stars flag

 

ESTABLISHMENT REQUIREMENTS FOR THE SPONSOR OR THE LEGAL REPRESENTATIVE



database

 

SUBMISSION OF CLINICAL TRIAL      INFORMATION


All details you will find here.

 
Source: EC
 

Related entries:

Brexit and EU rules for batch testing of medicinal products

Pharmaceutical industry Brexit preparedness and its legal consequences for MAH